（±）-雷西纳德的阻转异构体的发现与评估
Discovery and Assessment of Atropisomers of (±)-Lesinurad.
作者信息
Wang Jianfei, Zeng Wenqin, Li Shaohua, Shen Liang, Gu Zhengxian, Zhang Yang, Li Jian, Chen Shuhui, Jia Xiangbo
机构信息
WuXi AppTec , 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, P. R. China.
Sagacity New Drug R&D Co., Ltd. , 18 Zhenze Road, Xinwu District, Wuxi, Jiangsu 214135, P. R. China.
出版信息
ACS Med Chem Lett. 2017 Feb 14;8(3):299-303. doi: 10.1021/acsmedchemlett.6b00465. eCollection 2017 Mar 9.
Abstract
(+)- and (-)-Lesinurad were isolated as atropisomers from racemic lesinurad for the first time. No interconversion was observed between the two atropisomers under various conditions tested. The two atropisomers showed significant differences in hURAT1 highly expressed HEK293 cell-based inhibition assays, monkey pharmacokinetic studies, and human recombinant CYP2C9 stability studies. It was speculated that (+)-lesinurad might offer a better hyperuricemia/gout therapy than (-)-lesinurad or the racemate.
摘要
首次从外消旋雷西纳德中分离出（+）-和（-）-雷西纳德作为阻转异构体。在各种测试条件下，未观察到两种阻转异构体之间的相互转化。在基于高表达hURAT1的HEK293细胞的抑制试验、猴子药代动力学研究和人重组CYP2C9稳定性研究中，这两种阻转异构体表现出显著差异。据推测，（+）-雷西纳德可能比（-）-雷西纳德或外消旋体提供更好的高尿酸血症/痛风治疗效果。
相似文献
1
Discovery and Assessment of Atropisomers of (±)-Lesinurad.（±）-雷西纳德的阻转异构体的发现与评估
ACS Med Chem Lett. 2017 Feb 14;8(3):299-303. doi: 10.1021/acsmedchemlett.6b00465. eCollection 2017 Mar 9.
2
Characterization of Stereoselective Metabolism, Inhibitory Effect on Uric Acid Uptake Transporters, and Pharmacokinetics of Lesinurad Atropisomers.对 Lesinurad 对映异构体的立体选择性代谢、对尿酸摄取转运体的抑制作用及药代动力学特征的研究。
Drug Metab Dispos. 2019 Feb;47(2):104-113. doi: 10.1124/dmd.118.080549. Epub 2018 Nov 15.
3
Simulation of the impact of atropisomer interconversion on plasma exposure of atropisomers of an endothelin receptor antagonist.模拟阻转异构体互变对内皮素受体拮抗剂阻转异构体血浆暴露量的影响。
J Clin Pharmacol. 2004 Jul;44(7):680-8. doi: 10.1177/0091270004266622.
4
Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and CYP Enzyme Substrates Sildenafil, Amlodipine, Tolbutamide, and Repaglinide.评价新型选择性尿酸重吸收抑制剂乐瑞卡与 CYP 酶底物西地那非、氨氯地平、甲苯磺丁脲和瑞格列奈的药代动力学相互作用。
Clin Pharmacol Drug Dev. 2017 Jul;6(4):363-376. doi: 10.1002/cpdd.324. Epub 2017 Jan 9.
5
Efficacy and Safety of Lesinurad in Patients with Hyperuricemia Associated with Gout: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Lesinurad 治疗伴或不伴痛风的高尿酸血症患者的疗效和安全性：一项随机对照试验的系统评价和荟萃分析。
Pharmacotherapy. 2018 Nov;38(11):1106-1119. doi: 10.1002/phar.2183. Epub 2018 Oct 17.
6
Lesinurad: Evaluation of Pharmacokinetic and Pharmacodynamic Interactions With Warfarin in Healthy Volunteers.雷西纳德与华法林在健康志愿者中的药代动力学和药效学相互作用评价。
Clin Pharmacol Drug Dev. 2019 Jul;8(5):657-663. doi: 10.1002/cpdd.662. Epub 2019 Feb 13.
7
Discovery of Flexible Naphthyltriazolylmethane-based Thioacetic Acids as Highly Active Uric Acid Transporter 1 (URAT1) Inhibitors for the Treatment of Hyperuricemia of Gout.发现基于萘基三唑基甲烷的柔性硫代乙酸作为治疗痛风高尿酸血症的高活性尿酸转运蛋白1（URAT1）抑制剂。
Med Chem. 2017;13(3):260-281. doi: 10.2174/1573406412666160915163002.
8
Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and Commonly Used Drugs for Gout Treatment.评估新型选择性尿酸重吸收抑制剂乐瑞卡与常用痛风治疗药物的药代动力学相互作用。
Clin Pharmacol Drug Dev. 2017 Jul;6(4):377-387. doi: 10.1002/cpdd.323. Epub 2017 Jan 11.
9
Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.在高尿酸血症痛风患者中联合使用雷西纳德和非布司他的药效学、药代动力学及耐受性评估
Rheumatology (Oxford). 2014 Dec;53(12):2167-74. doi: 10.1093/rheumatology/ket487. Epub 2014 Feb 8.
10
Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout.雷西纳德治疗痛风患者高尿酸血症的疗效和安全性。
Drugs Context. 2019 May 29;8:212581. doi: 10.7573/dic.212581. eCollection 2019.
引用本文的文献
1
Nucleophilic aromatic substitutions enable diversity-oriented synthesis of heterocyclic atropisomers via non-atropisomeric intermediates.亲核芳香取代反应能够通过非阻转异构体中间体实现杂环阻转异构体的多样性导向合成。
Nat Commun. 2025 May 25;16(1):4856. doi: 10.1038/s41467-025-60101-z.
2
Iron-catalyzed stereoselective C-H alkylation for simultaneous construction of C-N axial and C-central chirality.铁催化的立体选择性C-H烷基化反应用于同时构建C-N轴手性和C-中心手性。
Nat Commun. 2024 Apr 25;15(1):3503. doi: 10.1038/s41467-024-47589-7.
3
Chirality of New Drug Approvals (2013-2022): Trends and Perspectives.新药批准的手性（2013-2022）：趋势与展望。
J Med Chem. 2024 Feb 22;67(4):2305-2320. doi: 10.1021/acs.jmedchem.3c02239. Epub 2024 Feb 12.
4
Dynamic Kinetic Resolution of Indole-Based Sulfenylated Heterobiaryls by Rhodium-Catalyzed Atroposelective Reductive Aldol Reaction.铑催化的阻转选择性还原羟醛反应实现吲哚基硫代化杂联芳基的动态动力学拆分
ACS Catal. 2023 Aug 30;13(18):12134-12141. doi: 10.1021/acscatal.3c03422. eCollection 2023 Sep 15.
5
High-throughput determination of enantiopurity in atroposelective synthesis of aryl triazoles.芳基三唑的对映选择性合成中对映体纯度的高通量测定
Chem Sci. 2023 May 11;14(22):5992-5999. doi: 10.1039/d3sc01559a. eCollection 2023 Jun 7.
6
Elagolix Sodium Salt and Its Synthetic Intermediates: A Spectroscopic, Crystallographic, and Conformational Study.Elagolix 钠盐及其合成中间体的光谱学、晶体学和构象研究。
Molecules. 2023 May 3;28(9):3861. doi: 10.3390/molecules28093861.
7
Catalytic Asymmetric Synthesis of Atropisomeric -Aryl 1,2,4-Triazoles.手性芳基 1,2,4-三唑的催化不对称合成。
J Org Chem. 2023 Jun 16;88(12):7815-7820. doi: 10.1021/acs.joc.2c02727. Epub 2023 Jan 27.
8
Advances in Atroposelectively De Novo Synthesis of Axially Chiral Heterobiaryl Scaffolds.轴向手性杂芳基骨架的新型选择性从头合成进展。
Molecules. 2022 Dec 3;27(23):8517. doi: 10.3390/molecules27238517.
9
Addressing Atropisomerism in the Development of Sotorasib, a Covalent Inhibitor of KRAS G12C: Structural, Analytical, and Synthetic Considerations.解决 Sotorasib（一种 KRAS G12C 的共价抑制剂）中立体异构现象的问题：结构、分析和合成方面的考虑。
Acc Chem Res. 2022 Oct 18;55(20):2892-2903. doi: 10.1021/acs.accounts.2c00479. Epub 2022 Sep 30.
10
Atropisomerism in the Pharmaceutically Relevant Realm.手性在药物相关领域的研究进展。
Acc Chem Res. 2022 Oct 18;55(20):2904-2919. doi: 10.1021/acs.accounts.2c00500. Epub 2022 Sep 26.
本文引用的文献
1
Stronger Uricosuric Effects of the Novel Selective URAT1 Inhibitor UR-1102 Lowered Plasma Urate in Tufted Capuchin Monkeys to a Greater Extent than Benzbromarone.新型选择性URAT1抑制剂UR-1102的促尿酸排泄作用更强，使簇绒卷尾猴的血浆尿酸水平降低的程度比苯溴马隆更大。
J Pharmacol Exp Ther. 2016 Apr;357(1):157-66. doi: 10.1124/jpet.115.231647. Epub 2016 Feb 23.
2
Investigational drugs for hyperuricemia.用于高尿酸血症的研究性药物。
Expert Opin Investig Drugs. 2015;24(8):1013-30. doi: 10.1517/13543784.2015.1051617. Epub 2015 Jun 14.
3
New medications in development for the treatment of hyperuricemia of gout.正在研发的用于治疗痛风高尿酸血症的新型药物。
Curr Opin Rheumatol. 2015 Mar;27(2):164-9. doi: 10.1097/BOR.0000000000000146.
4
Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.在高尿酸血症痛风患者中联合使用雷西纳德和非布司他的药效学、药代动力学及耐受性评估
Rheumatology (Oxford). 2014 Dec;53(12):2167-74. doi: 10.1093/rheumatology/ket487. Epub 2014 Feb 8.
5
ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload.ABCG2功能障碍由于肾尿酸排泄不足和肾尿酸过载导致高尿酸血症。
Sci Rep. 2014 Jan 20;4:3755. doi: 10.1038/srep03755.
6
New therapies for gout.痛风的新疗法。
Annu Rev Med. 2013;64:325-37. doi: 10.1146/annurev-med-080911-105830.
7
Hypouricemic effects of novel concentrative nucleoside transporter 2 inhibitors through suppressing intestinal absorption of purine nucleosides.新型集中核苷转运蛋白 2 抑制剂通过抑制嘌呤核苷的肠道吸收发挥降血尿酸作用。
Eur J Pharmacol. 2012 Sep 5;690(1-3):183-91. doi: 10.1016/j.ejphar.2012.06.015. Epub 2012 Jun 16.
8
High plasma uric acid concentration: causes and consequences.高血浆尿酸浓度：原因与后果。
Diabetol Metab Syndr. 2012 Apr 4;4:12. doi: 10.1186/1758-5996-4-12.
9
The prevalence of hyperuricemia in China: a meta-analysis.中国高尿酸血症的患病率：一项荟萃分析。
BMC Public Health. 2011 Oct 27;11:832. doi: 10.1186/1471-2458-11-832.
10
Assessing atropisomer axial chirality in drug discovery and development.评估药物研发中的阻转异构体轴向手性
J Med Chem. 2011 Oct 27;54(20):7005-22. doi: 10.1021/jm200584g. Epub 2011 Sep 15.
Zotero 插件